Navigation Links
McMaster researcher leads development of promising drug for inflammation
Date:3/30/2010

Hamilton, ON (March 30, 2010) Aspirin, ibuprofen and other non-steroidal anti-inflammatory drugs (NSAIDs) remain the most common treatment to relieve symptoms of arthritis and other inflammatory disorders. But despite their widespread use (around 2.5 million Canadians have osteoarthritis) these medications are also known to cause severe, sometimes life-threatening adverse effects within the body, particularly in the gastrointestinal tract.

A novel anti-inflammatory drug being developed and commercialized by an inflammation expert at McMaster University has shown promise in relieving symptoms of inflammation, while substantially reducing the incidence of bleeding and intestinal damage often caused by NSAIDs.

The research is published in the March issue of the British Journal of Pharmacology.

John Wallace, a pharmacologist and director of the Farncombe Family Digestive Health Research Institute at McMaster University, compared naproxen, a commonly used NSAID, to a novel anti-inflammatory drug, ATB-346, which he developed in collaboration with a team of Italian chemists and is now commercializing through his company, Antibe Therapeutics Inc.

ATB-346 is a derivative of naproxen which releases hydrogen sulfide. Evidence from animal studies suggests that in small quantities, hydrogen sulfide can protect the stomach from injury and can accelerate the healing of pre-existing ulcers.

"I've been working on NSAIDs for over 20 years," said Wallace, a professor of medicine in the Michael G. DeGroote School of Medicine at McMaster University. "This particular drug is, by far, the shining star. We've tested it in every model where it should fail, and it has performed exceptionally well."

To examine the gastrointestinal safety and anti-inflammatory effectiveness of ATB-346, Wallace and his co-investigators tested the drug in healthy rats as well as those with arthritis and inflammation. The researchers also examin
'/>"/>

Contact: Veronica McGuire
vmcguir@mcmaster.ca
90-552-591-402-2169
McMaster University
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Concussions not taken seriously enough: McMaster researcher
2. National Press Club to Host NEWSMAKER Media Briefing on Cornhusker Kickback With South Carolina Attorney General Henry McMaster
3. New drug shows promise for those with clotting disorders: McMaster researcher
4. Researchers identify potential new target for treating hepatitis C
5. Researchers Identify 2 Genes Linked to Fatty Liver Disease
6. NIA researchers find gene to explain mouse embryonic stem cell immortality
7. Researchers discover fundamental step in immune-system development
8. Scott & White Healthcare researchers studying investigational agent that targets breast cancer
9. SRI International Researchers to Present Work on Early Detection Tool for Neglected Tropical Diseases at 2010 American Chemical Society (ACS) Meeting
10. BUSM researcher receives prestigious young investigator award
11. Researchers find new chemotherapy combination shows promise in endometrial cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... from the University of Melbourne said this small increase ... benefits from CT scans in diagnosing and monitoring disease. ... British Medical Journal today and involved researchers at ... International Agency for Research on Cancer in Lyon, France. ... useful in providing detailed three dimensional pictures to diagnose ...
(Date:5/22/2013)... King of Prussia, PA (PRWEB) May 22, 2013 ... is proud to announce its participation in the Greater Philadelphia ... experienced cyclists and recreational riders who are passionate about stopping ... affects more than 25 million Americans. , The Tour ... Ambler Campus, located at 580 Meetinghouse Road in Ambler, 30 ...
(Date:5/22/2013)... 22, 2013 CoCENTRIX, a leading ... Health and Human Services and community providers, announced ... (ADMH) selected the CoCENTRIX Coordinated Care Platform ... the Health Records and coordinate care within and ... , CoCENTRIX is transitioning the hospitals' official records ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Hypervibe, a ... machines , announced today that the company’s US division ... Sunday, and Monday. Military personnel ordering the Hypervibe Performance ... when they show a valid military ID. Non-military customers ... that values commitment, honor, and integrity. These are values ...
(Date:5/22/2013)... Chicago, IL (PRWEB) May 22, 2013 ... and are looking for education on how to lose ... thresholds can be challenging and may demotivate people to ... A new study discussed this week on Medical ... that learning how to lose weight and actually losing ...
Breaking Medicine News(10 mins):Health News:Small increase in cancer risk following CT scans in childhood and adolescence 2Health News:PreDiabetes Centers to Appear at the Philadelphia Tour de Cure 2Health News:PreDiabetes Centers to Appear at the Philadelphia Tour de Cure 3Health News:The State of Alabama Selects the CoCENTRIX Coordinated Care Platform to Facilitate Care for Its Citizens Treated in State Psychiatric Hospitals 2Health News:The State of Alabama Selects the CoCENTRIX Coordinated Care Platform to Facilitate Care for Its Citizens Treated in State Psychiatric Hospitals 3Health News:Hypervibe Whole Body Vibration Offers First-Ever Sale This Memorial Day Weekend 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Break the Cycle of Obesity and Weight Gain With New Education For Patients on How to Lose Weight the Healthy Way 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Break the Cycle of Obesity and Weight Gain With New Education For Patients on How to Lose Weight the Healthy Way 3
... researcher has co-authored an international study that revealed a drug ... a rare lung disease in women. The life-threatening disease ... The clinical trial of the drug -- called sirolimus -- ... therapy for the lung disease, lymphangioleiomyomatosis, or LAM. LAM ...
... The wrist size of overweight or obese children and teens ... says a new study. Italian researchers measured the wrist ... They also used a painless nuclear imaging technique on about ... areas of the wrist more precisely. Blood tests were ...
... MONDAY, April 11 (HealthDay News) -- A drug commonly prescribed ... treating the mild stage of the disease, a new study ... effective in treating moderate to severe Alzheimer,s disease, "in mild ... works," said lead researcher Dr. Lon S. Schneider, a professor ...
... new discovery published online in The FASEB Journal ( ... likely to benefit from breast cancer drug therapies. If ... it would represent a significant advance for breast cancer ... some people. In addition, some drugs have side effects ...
... How your carotid artery moves can reveal your risk of ... study this vessel aspect in more detail thanks to a ... with suspected coronary artery disease, reveals a thesis from the ... arteries is associated with a risk of future heart disease, ...
... the journal Investigational New Drugs and conducted by researchers ... molecule inhibitors are showing promise in blocking STAT3, a ... osteosarcoma. These small molecule inhibitors one derived from ... as a new, non-toxic treatment for these deadly tumors. ...
Cached Medicine News:Health News:OHSU expert co-authors study finding treatment for rare lung disease 2Health News:Drug Memantine Ineffective for Mild Alzheimer's, Study Finds 2Health News:Drug Memantine Ineffective for Mild Alzheimer's, Study Finds 3Health News:Tiny antibody fragments raised in camels find drug targets in human breast cancer cells 2Health News:New potential atherosclerosis risk marker discovered 2Health News:New study finds compounds show promise in blocking STAT3 signaling as treatment for osteosarcoma 2
(Date:5/22/2013)... VANCOUVER, British Columbia , May 22, 2013  OncoGenex ... the development of novel therapeutics to target mechanisms of treatment ... investigational compounds, custirsen and OGX-427, will be presented as "Trials ... of the American Society of Clinical Oncology (ASCO) in ... 4. Despite the availability of drugs that ...
(Date:5/21/2013)... , May 21, 2013 Reaching a ... process, the National Association of Boards of Pharmacy ® ... the .PHARMACY domain suffix has passed the Internet Corporation ... intends to launch the .PHARMACY gTLD by the end ... to legitimate online pharmacies and related entities that are ...
(Date:5/21/2013)... SAN FRANCISCO , May 21, 2013 /PRNewswire/ ... meeting of the American Psychiatric Association show that ... statistically and clinically meaningful response and remission in ... acute phase of therapy, which were maintained through ... acute treatment, 62 percent of patients achieved symptomatic ...
Breaking Medicine Technology:OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 2OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 3OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 4OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 5NABP's .PHARMACY Proposal Passes Initial ICANN Evaluation 2NABP's .PHARMACY Proposal Passes Initial ICANN Evaluation 3New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System 2New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System 3New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System 4
... TOKYO and CHIPPENHAM, England, October 7 ,Sosei ... and Vectura,Group plc ("Vectura"; LSE: VEC), announce ... efficacy, safety and tolerability of NVA237 presented ... Society (ERS) in Berlin,Germany. The new data ...
... of Gastroenterology Annual ... ... two Phase 3,studies presented at the American College of Gastroenterology Annual,Scientific ... rates than lansoprazole among patients with more,severe grades of erosive esophagitis ...
Cached Medicine Technology:NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed 2Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: